Medexus Pharmaceuticals (TSE:MDP) Stock Rating Lowered by Stifel Canada

Medexus Pharmaceuticals (TSE:MDP) was downgraded by analysts at Stifel Canada from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

A number of other research firms also recently issued reports on MDP. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the stock from C$6.00 to C$3.45 in a research report on Friday. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research note on Wednesday, January 8th. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Finally, Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of C$5.49.

Medexus Pharmaceuticals Trading Up 5.2 %

MDP stock opened at C$3.21 on Thursday. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56. The stock has a 50-day moving average price of C$3.53 and a 200-day moving average price of C$2.82. The firm has a market cap of C$78.74 million, a PE ratio of 64.20 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.